BR112015003919A2 - compostos pró-neurogênicos - Google Patents

compostos pró-neurogênicos

Info

Publication number
BR112015003919A2
BR112015003919A2 BR112015003919A BR112015003919A BR112015003919A2 BR 112015003919 A2 BR112015003919 A2 BR 112015003919A2 BR 112015003919 A BR112015003919 A BR 112015003919A BR 112015003919 A BR112015003919 A BR 112015003919A BR 112015003919 A2 BR112015003919 A2 BR 112015003919A2
Authority
BR
Brazil
Prior art keywords
compounds
disease
neurogenesis
postnatal
normal aging
Prior art date
Application number
BR112015003919A
Other languages
English (en)
Portuguese (pt)
Inventor
A Pieper Andrew
K De Brabander Jef
M Ready Joseph
L Mcknight Steven
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Priority claimed from US13/594,223 external-priority patent/US9962368B2/en
Publication of BR112015003919A2 publication Critical patent/BR112015003919A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112015003919A 2012-08-24 2012-08-24 compostos pró-neurogênicos BR112015003919A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/594,223 US9962368B2 (en) 2009-01-09 2012-08-24 Pro-neurogenic compounds
PCT/US2012/052283 WO2014031125A1 (fr) 2012-08-24 2012-08-24 Composés pro-neurogènes

Publications (1)

Publication Number Publication Date
BR112015003919A2 true BR112015003919A2 (pt) 2017-07-04

Family

ID=50150277

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015003919A BR112015003919A2 (pt) 2012-08-24 2012-08-24 compostos pró-neurogênicos

Country Status (8)

Country Link
EP (1) EP2925129A4 (fr)
JP (1) JP6231566B2 (fr)
CN (2) CN108329253A (fr)
AU (2) AU2012388221B2 (fr)
BR (1) BR112015003919A2 (fr)
CA (1) CA2882923A1 (fr)
IL (1) IL237341A0 (fr)
WO (1) WO2014031125A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102083830B (zh) 2008-03-24 2014-11-12 梅迪维新技术公司 吡啶并[3,4-b]吲哚和应用方法
JP5586577B2 (ja) 2008-03-24 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 架橋複素環化合物およびその使用
JP5551708B2 (ja) 2008-10-31 2014-07-16 メディベイション テクノロジーズ， インコーポレイテッド アゼピノ［４，５−ｂ］インドール化合物およびその使用方法
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
AU2010203356B2 (en) 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9162980B2 (en) 2009-01-09 2015-10-20 Board Of Regents Of The University Of Texas System Anti-depression compounds
BRPI1006602A2 (pt) 2009-04-29 2019-01-15 Medivation Technologies Inc composto, método para modular um receptor de histamina em um indivíduo, composição farmacêutica, kit e método para tratar um distúrbio cognitivo ou um distúrbio induzido por pelo menos um sintoma associado com a alteração da cognição
JP5779183B2 (ja) 2009-09-23 2015-09-16 メディベイション テクノロジーズ， インコーポレイテッド ピリド［４，３−ｂ］インドールおよび使用方法
WO2011038164A1 (fr) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Composés hétérocycliques pontés et leurs méthodes d'utilisation
CN102724875B (zh) 2009-09-23 2015-05-27 梅迪维新技术公司 吡啶并[3,4-b]吲哚化合物及其使用方法
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103460A1 (fr) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Dérivés de pyrido[4,3-b]indole et pyrido[3,4-b]indole tétracyclique condensés et procédés d'utilisation
US9187471B2 (en) 2010-02-19 2015-11-17 Medivation Technologies, Inc. Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
DK2590647T3 (en) 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds
AU2012254158B2 (en) 2011-02-18 2016-02-04 Medivation Technologies, Inc. Compounds and methods of treating diabetes
WO2012112965A1 (fr) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Composés et procédés de traitement du diabète
US9199985B2 (en) 2011-02-18 2015-12-01 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (fr) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Dérivés de pyrido[4,3-b]indole et de pyrido[3,4-b]indole et procédés d'utilisation
JP6377054B2 (ja) 2012-05-11 2018-08-22 リセット セラピューティークス， インコーポレイテッド クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
AU2013305591B2 (en) 2012-08-24 2017-04-13 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2015070234A2 (fr) * 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Composés neuroprotecteurs et leur utilisation
WO2015070237A1 (fr) 2013-11-11 2015-05-14 Board Of Regents Of The University Of Texas System Produits chimiques neuroprotecteurs et leurs procédés d'identification et d'utilisation
TWI690521B (zh) * 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
JP7327039B2 (ja) * 2019-09-25 2023-08-16 富士通株式会社 活動量管理プログラム、活動量管理システム、及び活動量管理方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1094063A1 (fr) * 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Pipérazinylalkyl)carbazoles comme modulateurs de Bax
AU2002228316A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Carbazole derivatives and their uses as heparanase inhibitors
US20070203236A1 (en) * 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
WO2009082268A2 (fr) * 2007-12-21 2009-07-02 Alla Chem, Llc Ligands dalpha-adrénorécepteurs, de récepteurs de dopamine, de l'histamine, d'imidazoline et de sérotonine ainsi que leurs procédés d'utilisation
RU2544856C2 (ru) * 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP5588991B2 (ja) * 2008-10-31 2014-09-10 メディベイション テクノロジーズ， インコーポレイテッド 剛性の部分を有するピリド［４，３−ｂ］インドール
AU2010203356B2 (en) * 2009-01-09 2015-11-26 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US8362277B2 (en) * 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
WO2011054851A1 (fr) 2009-11-05 2011-05-12 Glaxosmithkline Llc Nouveau procédé
DK2590647T3 (en) * 2010-07-07 2018-02-12 Univ Texas Pro-neurogenic compounds

Also Published As

Publication number Publication date
CN104754941A (zh) 2015-07-01
JP6231566B2 (ja) 2017-11-15
AU2017268635A1 (en) 2017-12-21
CN108329253A (zh) 2018-07-27
AU2012388221B2 (en) 2017-08-31
EP2925129A1 (fr) 2015-10-07
CN104754941B (zh) 2018-02-27
WO2014031125A1 (fr) 2014-02-27
JP2015529663A (ja) 2015-10-08
CA2882923A1 (fr) 2014-02-27
EP2925129A4 (fr) 2016-06-08
IL237341A0 (en) 2015-04-30
AU2012388221A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
BR112015003919A2 (pt) compostos pró-neurogênicos
BR112013000414A2 (pt) compostos proneurogênicos
BR112014027571A2 (pt) métodos para o tratamento de retinopatia diabética e outras doenças oftalmológicas
WO2018060732A3 (fr) Compositions et méthodes de traitement de troubles épileptiques
ECSP19048477A (es) Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades
GT201300324A (es) Nuevos compuestos inhibidores de la fosfodiesterasa tipo 10a
CL2019000534A1 (es) Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades.
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
BR112012025558A2 (pt) tratamento para a ataxia-telangiectasia
BR112014007654A8 (pt) Inibidores de lrrk2 quinase macrocíclicos.
BR112012022552A2 (pt) uso de fenoterol e de anélogos de fenoterol no tratamento de gliobastomas e astrocitomas
BR112014004741A2 (pt) pelo menos uma entidade química; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
WO2014184576A3 (fr) Administration de substances médicamenteuses
BR112015004942A2 (pt) benzimidazóis como agentes ativos do snc
CA2864606C (fr) Procedes de traitement et de prevention de maladies et de troubles du systeme nerveux central
IN2013DN11328A (fr)
BR112014014802A2 (pt) composto, composição farmacêutica, uso de um composto, métodos para tratamento ou para alívio de uma doença ou de um distúrbio ou de uma condição, e para tratamento ou melhora de doenças ou de condições
BR112015007095A2 (pt) derivados de di-hidro-6-azafenaleno para o tratamento de doenças do snc, oncológicas e distúrbios relacionados
WO2012068553A3 (fr) Méthodes de diagnostic et de traitement de maladies neurodégénératives
Lule et al. Neurodevelopmental and neurodegenerative diseases–Is there a pathophysiological link? Attention-deficit/hyperactivity disorder and amyotrophic lateral sclerosis as examples
BR112012033695A2 (pt) tratamento com l-metilfolato para distúrbios psiquiátricos ou neurológicos.
Mariniello et al. Abducens nerve palsy as the unique sign of a trigeminal schwannoma
Piradov et al. P 219. Navigated repeated transcranial magnetic stimulation in stroke rehabilitation (randomized blind sham-controlled study), Preliminary results: safety and tolerability
BR112022000874A2 (pt) Composições e métodos para o tratamento de síndrome de sanfilippo e outras doenças

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements